Amylyx’s ALS Drug Should Wait For Phase III Results, US FDA Panel Says

 
• By Sue Sutter

Six of 10 advisory committee members say Phase II CENTAUR trial cannot stand on its own to support approval at this time. However, patients and advocates say thousands will die if they have to wait for the Phase III PHOENIX trial to complete in 2024 before the drug becomes widely available.

Bird on one leg
This bird may be able to stand on one leg, but Amylyx's ALS drug cannot, an FDA committee said. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers